Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is.

Genes & development - 1 Sept 2018

Liao Sida, Maertens Ophélia, Cichowski Karen, Elledge Stephen J

Abstract excerpt

Bromodomain and extraterminal (BET) domain inhibitors (BETis) show efficacy on NUT midline carcinoma (NMC). However, not all NMC patients respond, and responders eventually develop resistance and relapse. Using CRISPR and ORF expression screens, we systematically examined the ability of cancer drivers to mediate resistance of NMC to BETis and uncovered six general classes/pathways mediating resistance. Among...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azepines
Share to Cyclin-Dependent Kinase 4
Share to Cyclin-Dependent Kinase 6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to E2F Transcription Factors

Share to Kruppel-Like Factor 4

Share to Monomeric GTP-Binding Proteins

Share to Oncogene Proteins

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 30135075
DOI: 10.1101/gad.315648.118
PMCID: PMC6120715

Genes

BRD4
CDK4
KLF4
MYC
RRAS2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is.PMID 30135075Read ↗

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline CarcinomaSemantic proximity Read ↗

SETD2 and miR-21 as therapeutic targets for NUT midline carcinomaSemantic proximity Read ↗

Pathogenesis of NUT Midline CarcinomaSemantic proximity Read ↗

Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734Semantic proximity Read ↗

SETD2 Deficiency and miR-21: Potent Therapeutic Targets in NUT Midline CarcinomaSemantic proximity Read ↗

NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatmentSemantic proximity Read ↗

The expanding universe of NUTM1 fusions in pediatric cancerSemantic proximity Read ↗

Novel BRD4–NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinomaSemantic proximity Read ↗

<i>Brd4::Nutm1</i> fusion gene initiates NUT carcinoma <i>in vivo</i>Semantic proximity Read ↗

EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genesSemantic proximity Read ↗

Inhibition of NF-κB–Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal MelanomaSemantic proximity Read ↗

Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.